STTK

Company Overview — What Does Shattuck Labs, Inc. Do?

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas. Shattuck Labs, Inc. (STTK) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Taylor H. Schreiber and employs approximately 100 people. With a market capitalization of $447M, STTK is one of the notable companies in the Healthcare sector.

Shattuck Labs, Inc. (STTK) Stock Rating — Hold (April 2026)

As of April 2026, Shattuck Labs, Inc. receives a Hold rating with a composite score of 39.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.STTK ranks #910 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Shattuck Labs, Inc. ranks #64 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

STTK Stock Price and 52-Week Range

Shattuck Labs, Inc. (STTK) currently trades at $7.05. The stock lost $0.35 (4.7%) in the most recent trading session. The 52-week high for STTK is $6.26, which means the stock is currently trading 12.5% from its annual peak. The 52-week low is $0.69, putting the stock 918.5% above its annual trough. Recent trading volume was 472K shares, suggesting relatively thin trading activity.

Is STTK Overvalued or Undervalued? — Valuation Analysis

Shattuck Labs, Inc. (STTK) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.89x, versus the sector average of 2.75x. The price-to-sales ratio is 121.39x, compared to 1.66x for the average Healthcare stock.

At current multiples, Shattuck Labs, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Shattuck Labs, Inc. Profitability — ROE, Margins, and Quality Score

Shattuck Labs, Inc. (STTK) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -64.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -58.1% versus the sector average of -33.1%.

On a margin basis, Shattuck Labs, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -834.8% (sector: -66.1%). Net profit margin stands at -781.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -37.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

STTK Debt, Balance Sheet, and Financial Health

Shattuck Labs, Inc. has a debt-to-equity ratio of 10.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 11.70x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $43M.

STTK has a beta of 1.30, meaning it is more volatile than the broader market — a $10,000 investment in STTK would be expected to move 30.5% more than the S&P 500 on any given day. The stability factor score for Shattuck Labs, Inc. is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Shattuck Labs, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Shattuck Labs, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.70. Net income for the quarter was $-53M. Gross margin was 100.0%. Operating income came in at $-56M.

In FY 2025, Shattuck Labs, Inc. reported revenue of $1M and earnings per share (EPS) of $-0.70. Net income for the quarter was $-49M. Revenue grew -82.5% year-over-year compared to FY 2024. Operating income came in at $-52M.

In Q3 2025, Shattuck Labs, Inc. reported revenue of $1M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-10M. Revenue grew -66.6% year-over-year compared to Q3 2024. Operating income came in at $-11M.

In Q2 2025, Shattuck Labs, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.24. Net income for the quarter was $-12M. Operating income came in at $-13M.

Over the past 8 quarters, Shattuck Labs, Inc. has demonstrated a growth trajectory, with revenue expanding from $2M to $4M. Investors analyzing STTK stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

STTK Dividend Yield and Income Analysis

Shattuck Labs, Inc. (STTK) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

STTK Momentum and Technical Analysis Profile

Shattuck Labs, Inc. (STTK) has a momentum factor score of 78/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 35/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

STTK vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Shattuck Labs, Inc. (STTK) ranks #64 out of 838 stocks based on the Blank Capital composite score. This places STTK in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing STTK against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full STTK vs S&P 500 (SPY) comparison to assess how Shattuck Labs, Inc. stacks up against the broader market across all factor dimensions.

STTK Next Earnings Date

No upcoming earnings date has been announced for Shattuck Labs, Inc. (STTK) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy STTK? — Investment Thesis Summary

Shattuck Labs, Inc. presents a balanced picture with arguments on both sides. The quality score of 23/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Price momentum is positive at 78/100, suggesting the trend favors buyers. High volatility (stability score 22/100) increases portfolio risk.

In summary, Shattuck Labs, Inc. (STTK) earns a Hold rating with a composite score of 39.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on STTK stock.

Related Resources for STTK Investors

Explore more research and tools: STTK vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare STTK head-to-head with peers: STTK vs AZN, STTK vs SLGL, STTK vs VMD.